Detection of in vivo atherosclerotic plaque progression with a fibrin-targeted MR contrast agent
- 886 Downloads
KeywordsAtherosclerotic Plaque Pravastatin Brachiocephalic Artery Plaque Development Gadolinium Concentration
Molecular MRI has emerged as a promising, non-invasive modality to accurately detect high-risk atherosclerotic plaques. Due to the inherently low sensitivity of MRI, contrast agents targeted at an abundant and robust component of the lesion are required. Fibrin represents a clinically relevant target and imaging of aortic, coronary, carotid and cardiac thrombi have been demonstrated both in animal models and men. It has been recognised as an important component of atherosclerotic plaques and is present throughout plaque development.
This study aimed to investigate the feasibility of intra-plaque fibrin detection throughout plaque development with EP-2104R, a fibrin targeted contrast agent, in an in vivo mouse model of progressive atherosclerosis.
Male C57BL/6 apolipoprotein E-knockout mice (ApoE -/-) were fed a high fat diet (HFD) for 4, 8 and 12 weeks prior to MRI of their brachiocephalic artery pre- and post i.v. administration of EP-2104R. A fourth group of mice were treated with pravastatin during the 12 week HFD period. MRI was performed on a 3 T scanner (Philips Achieva, Best, Netherlands). A cardiac-triggered inversion-recovery gradient-echo sequence was used for contrast detection. Both the CNR and T1 relaxation time within the plaques were determined and compared to the absolute gadolinium concentration measured by inductively coupled mass spectroscopy (ICP-MS). Histological sections were stained with MSB for fibrin visualization and compared to MRI.
These results demonstrate the feasibility of intraplaque fibrin detection using EP-2104R. Direct fibrin imaging could be potentially useful for the detection of vulnerable coronary atherosclerotic lesions during the development of disease in vivo, which could aid earlier diagnosis and intervention.
This article is published under license to BioMed Central Ltd.